Rathi Pillai, MD

Sponsored Research Projects

• A Phase III, Open Label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non-Sm
• A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following De
• CA209-026: An Open-Label, Randomized Phase 3 Trial of Nivolumab versus Investigator's choice
• CA209-817: Phase IIIb/IV Trial of Flat Dose Nivolumab w/ Ipilimumab